ALTERNATIVE TO PTO/SB/08A/B
(Based on PTO 08-08 version)

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 2

Complete if Known	
Application Number	09/475,704
Filing Date	December 30, 1999
First Named Inventor	Susan W. BARNETT
Art Unit	1635
Examiner Name	J. S. Pitrak
Attorney Docket Number	PAT051386-US-NP

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] *(if known)*	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1.	US-5,738,852-A	04-14-1998	Robinson et al.	
	2.	US-5,858,646-A	01-12-1999	Kang et al.	
	3.	US-6,610,476-B1	08-26-2003	Chang et al.	
	4.	US-7,211,659-B2	05-01-2007	zur Megede et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document Country Code[3]-Number[4]-Kind Code[5] *(if known)*	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T[6]
	5.	WO-90/10230	09-07-1990	University of Ottawa		
	6.	WO-98/26075	06-18-1998	Institut National De La Sante et De La Recherche Medicale - Inserm	Translation of abstract only.	
	7.	WO-03/20876	03-13-2003	Chiron Corp.		

Examiner Signature		Date Considered	

*EXAMINER: Initial if information considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
	8.	BARNETT et al. (1999). "DNA vaccines coming of age," *Annual Rep Med Chem* 34, Chapter 15, pages 149-158.	
	9.	BARNETT et al. (June 2001). "The ability of an oligomeric human immunodeficiency virus type 1 (HIV-1) envelope antigen to elicit neutralizing antibodies against primary HIV-1 isolates is improved following partial deletion of the second hypervariable region," *J Virol.* 75(12):5526-40.	
	10.	BRUSIC et al. (1998). "Prediction of MHC class II-binding peptides using an evolutionary algorithm and artificial neural network," *Bioinformatics* 14(2):121-30.	
	11.	CARTER, (1994) "Epitope Mapping of a Protein Using the Geysen (PEPSCAN) Procedure," *Methods Mol. Biol.* 36:207-23.	
	12.	CHANG et al. (August 2000). "Human immunodeficiency virus type 1 subtype E envelope recombinant peptides containing naturally immunogenic epitopes," *J Infect Dis.* 182(2):442-50.	
	13.	DAI, L. C., et al. (1992) "Mutation of human immunodeficiency virus type 1 at amino acid 585 on gp41 results in loss of killing by CD8+ A24-restricted cytotoxic T lymphocytes," *J. Virol.* 66(5):3151-3154.	
	14.	DAVENPORT et al. (1995) "An empirical method for the prediction of T-cell epitopes," *Immunogenetics* 42:392-97.	
	15.	DESROSIERS, R. C., (2004). "Prospects for an AIDS vaccine," *Nat. Med.* 10(3):221-223.	
	16.	FELLER & DE LA CRUZ, (1991). "Identifying antigenic T-cell sites," *Nature* 349(6311):720-721.	

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 2 of 2

Complete if Known	
Application Number	09/475,704
Filing Date	December 30, 1999
First Named Inventor	Susan W. BARNETT
Art Unit	1635
Examiner Name	J. S. Pitrak
Attorney Docket Number	PAT051386-US-NP

	17.	FENOGLIO, D., et al., (2000). "Natural analogue peptides of HIV-1 gp120 T-helper epitope antagonize response of gp120-specific human CD4 T-cell clones," *J AIDS* 23:1-7.	
	18.	GEYSEN et al. (1984). "Use of peptide synthesis to probe viral antigens for epitopes to a resolution of a single amino acid," *Proc. Natl. Acad. Sci. USA* 81:3998-4002.	
	19.	HEENEY et al., (1999). "HIV-1 vaccine-induced immune responses which correlate with protection from SHIV infection: compiled preclinical efficacy data from trials with ten different HIV-1 vaccine candidates," *Immunology Letters* 66:189-195.	
	20.	HOPP, (1993). "Retrospective: 12 Years of Antigenic Determinant Predictions and More," *Peptide Research* 6:183-90.	
	21.	Instructions to Authors, 2008, *J. Virol.* 82(1):1-19.	
	22.	JAMESON et al., (1988). "The antigenic index: a novel algorithm for predicting antigenic determinants," *Comput. Appl. Biosci.* 4(1):1818-1886.	
	23.	JOHNSON, P. R., et al., (1992). "Identification of overlapping HLA class I-restricted cytotoxic T cell epitopes in a conserved region of the human immunodeficiency virus type 1 envelope glycoprotein: definition of minimum epitopes and analysis of the effects of sequence variation," *J. Exp. Med.* 175:961-971.	
	24.	KOLASKAR et al. (1990). "A semi-empirical method for prediction of antigenic determinants on protein antigens." *FEBS Lett.* 276:172-174.	
	25.	LEE et al., (2000). "A single point mutation in HIV-1 V3100p alters the immunogenic properties of rgp120," *Arch Virol.* 145(10):2087-2103.	
	26.	LIU, Y., et al., (2006). "Selection on the human immunodeficiency virus type 1 proteome following primary infection," *J. Virol.* 80(19):9519-9529.	
	27.	MAKSYUTOV & ZAGREBELNAYA, (1993). "ADEPT: a computer program for prediction of protein antigenic determinants," *Comput. Appl. Biosci.* 9(3):291-297.	
	28.	MCLAIN, L., et al., (2001). "Different effects of a single amino acid substitution on three adjacent epitopes in the gp41 C-terminal tall of a neutralizing antibody escape mutant of human immunodeficiency virus type 1," *Arch. Virol.* 146:157-166.	
	29.	MEISTER et al., (1995). "Two novel T cell epitope prediction algorithms based on MHC-binding motifs; comparison of predicted and published epitopes from Mycobacterium tuberculosis and HIV protein sequences," *Vaccine* 13(6):581-591.	
	30.	PANTALEO, G., and R. A. Koup, (2004). "Correlates of immune protection in HIV-1 infection: what we know, what we don't know, what we should know," *Nat. Med.* 10(8):806-810.	
	31.	ROBERTS et al., (1996). "Prediction of HIV Peptide Epitopes by a Nova1 Algorithm," *AIDS Res. Hum. Retroviruses* 12(7):593-610.	
	32.	VERSCHOOR, (1999). "Comparison of immunity generated by nucleic acid, MF59 and iscom-formulated HIV-1 Gp120 vaccines in rhesus macaques," *J Med Primatol* 28(4/5):Abstract #37	
	33.	WATKINS, B. A., et al., (1993). "Immune escape by human immunodeficiency virus type 1 from neutralizing antibodies: evidence for multiple pathways," *J. Virol.* 67(12):7493-7500.	
	34.	WELLING et al., (1985). "Prediction of sequential antigenic regions in proteins," *FEBS Lett.* 188:215-18,	
	35.	zur MEGEDE et al., (2006). "Evaluation of human immunodeficiency type 1 subtype C gag, pol, and gagpol DNA and alphavirus replicon vaccines," *Vaccine* 24:2755-2763.	
	36.	zur MEGEDE et al., (June 2003). "Expression and Immunogenicity of Sequence-modified Human Immunodeficiency Virus Type 1 Subtype B pol and gagpol DNA Vaccines," *J Virol.* 77(11):6197-6207.	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
[1]Applicant's unique citation designation number (optional). [2]Applicant is to place a check mark here if English language Translation is attached.